04, 2025 (GLOBE NEWSWIRE) -- Noom , the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1 Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate
A GLP-1 Receptor Agonist Liraglutide Inhibits Endothelial Cell Dysfunction and Vascular Adhesion Molecule Expression in an ApoE-/- Mouse Model
Over the course of this interview, she shares how she evaluates peptides, why gut function is foundational to hormone optimization, how she approaches GLP1 microdosing, and what she watches for in long-term care
Even small changes in medication absorption can make a difference, she adds
Ozempic Label Updated to Include Blocked Intestines as Potential Side Effect